^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG CLASS:

Topoisomerase II inhibitor

Related drugs:
20h
Blood Brain Barrier (BBB) Disruption Using Exablate Focused Ultrasound With Doxorubicin for Treatment of Pediatric DIPG (clinicaltrials.gov)
P1/2, N=10, Active, not recruiting, InSightec | Recruiting --> Active, not recruiting | Trial completion date: Jul 2026 --> Oct 2026 | Trial primary completion date: Jan 2026 --> Jun 2026
Enrollment closed • Trial completion date • Trial primary completion date
|
doxorubicin hydrochloride
1d
Smart Magnetic Nanozyme for Multimodal Dynamic Regulation to Reverse Multidrug Resistance in Breast Cancer. (PubMed, Mol Pharm)
Intratumoral redox homeostasis is often implicated in the development of multidrug resistance (MDR), which compromises the oxidative cytotoxicity of anthracycline chemotherapeutics such as doxorubicin (DOX)...As a result of this engineered therapeutic approach, the combination therapy reduced the IC50 of DOX by 87.7-fold compared to free DOX. In summary, this multimodal nanozyme provides a novel strategy to target redox homeostasis and overcome MDR in cancer therapy.
Journal
|
TRPA1 (Transient Receptor Potential Cation Channel Subfamily A Member 1)
|
doxorubicin hydrochloride
1d
Piceid as a promising candidate for multi-target adjunctive therapeutic for inflammation-associated cervical cancer progression: an in silico approach. (PubMed, In Silico Pharmacol)
Piceid exhibited dose-dependent cytotoxicity against HeLa cervical cancer cells, inducing marked morphological alterations, although with a higher IC₅₀ than doxorubicin. These findings suggest that piceid may serve as a promising candidate for multi-target immune-modulatory activity to prevent the progress of Cervical Cancer.
Journal
|
TGFBR2 (Transforming Growth Factor Beta Receptor 2) • CASP8 (Caspase 8)
|
doxorubicin hydrochloride
1d
An Active-Targeted ZIF8-Based Nanotheranostic Platform for Ultrasound Imaging-Guided Synergistic Therapy of Triple-Negative Breast Cancer. (PubMed, Int J Nanomedicine)
FA-PEG@ZIF8@CIP was constructed as a folic acid-polyethylene glycol-functionalized ZIF8 nanoplatform for the delivery of ciprofloxacin...This multifunctional nanosystem enables the integration of diagnosis and therapy and represents a promising strategy for TNBC treatment. By combining targeted delivery, pH-responsive drug release, ultrasound imaging, and synergistic therapeutic effects within a single platform, FA-PEG@ZIF8@CIP may offer a valuable approach for improving theranostic outcomes in TNBC.
Journal
|
CD8 (cluster of differentiation 8) • HMGB1 (High Mobility Group Box 1) • CALR (Calreticulin)
1d
Linkage Between miR-218-2 (rs11134527) Genetic Polymorphism and Breast Cancer Risk: A Case-Control Study in the Bangladeshi Women. (PubMed, Health Sci Rep)
Chemotherapy was the principal treatment (62.12%), with cyclophosphamide (69.62%), doxorubicin (53.80%), and paclitaxel (56.33%) as the most prescribed agents. Significant associations were also observed under the recessive model (AA vs. GG + AG: OR = 1.96, 95% CI = 1.0-3.86, p = 0.051) and the allelic model (A vs G: OR = 1.59, 95% CI = 1.06-2.39, p = 0.026). The miR-218-2 rs11134527 A allele confers an increased risk of breast cancer in Bangladeshi women, supporting its potential role as a population-specific genetic biomarker for susceptibility assessment.
Journal
|
MIR218 (MicroRNA 218)
|
paclitaxel • doxorubicin hydrochloride • cyclophosphamide
1d
Inhibition of PTCH1 drug efflux activity enhances chemotherapy efficacy against triple negative breast cancers. (PubMed, Transl Oncol)
We have identified a small molecule produced by a marine sponge as being able to inhibit PTCH1 efflux activity and increase the efficacy of vemurafenib treatment on BRAF-mutated melanoma cells in vitro and in vivo in mice. We found that inhibiting PTCH1 drug efflux activity significantly increased the cytotoxic effect of chemotherapies such as doxorubicin and docetaxel in three TNBC cell lines. Overall, our findings suggest that PTCH1 plays a role in the resistance of TNBC cells to chemotherapy, and that using a PTCH1 efflux inhibitor during neoadjuvant or adjuvant therapy could enhance the efficacy of treatment against PTCH1-expressing TNBC, while preventing treatment resistance, relapse, and metastasis formation.
Journal
|
BRAF (B-raf proto-oncogene) • PTCH1 (Patched 1)
|
BRAF mutation
|
Zelboraf (vemurafenib) • docetaxel • doxorubicin hydrochloride
2d
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer (clinicaltrials.gov)
P1/2, N=25, Recruiting, Teclison Ltd. | Trial completion date: Dec 2025 --> Sep 2028 | Trial primary completion date: Dec 2025 --> Mar 2028
Trial completion date • Trial primary completion date
|
Tirazone (tirapazamine)
3d
Bridging In Silico Design and Experimental Validation: Virtual Screening and In Vitro Assessment of Biomimetic Anticancer Peptides Inspired by Horseshoe Crab Hemolymph Proteins. (PubMed, Eur J Pharm Sci)
This integrated approach successfully identified H22 as a hemocyanin-derived peptide with moderately potent anticancer activity and promising selectivity. The workflow provides a reproducible proof‑of‑concept framework for computational-guided peptide, warranting further optimization and experimental validation.
Preclinical • Journal
|
CASP9 (Caspase 9) • CASP7 (Caspase 7)
|
doxorubicin hydrochloride
3d
Apoptosis enhancement in MCF-7 cells: Synergistic effects of doxorubicin and the novel sulfonamide Zm-093. (PubMed, Int J Immunopathol Pharmacol)
These findings confirm that DOX and Zm-093 exhibit synergistic effects on apoptotic pathways in MCF-7 cells, highlighting the potential of Zm-093 as a novel therapeutic agent with improved efficacy and reduced toxicity compared to existing sulfonamide compounds.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3)
|
doxorubicin hydrochloride
4d
MnUA-DOX-artesunate hydrogel remodels immunosuppressive tumor microenvironment and prevents postoperative recurrence in triple-negative breast cancer. (PubMed, J Nanobiotechnology)
In this study, we developed an injectable multifunctional hydrogel, MND-ART-GEL, by encapsulating immunostimulatory manganese urate (MnUA), the chemotherapeutic agent doxorubicin (DOX), and an artemisinin derivative, artesunate (ART), within a thermosensitive Pluronic F127 matrix...In orthotopic and postsurgical TNBC mouse models, MND-ART-GEL significantly inhibited tumor growth and recurrence, remodeled the immunosuppressive tumor microenvironment, enhanced CD8+ T-cell infiltration, dendritic cell maturation, and M1 macrophage polarization, reduced PD-1/PD-L1 expression on CD8+ T cells, and promoted the secretion of immune-related cytokines. This study presents a localized drug delivery strategy that integrates chemotherapy, immune modulation, and multitarget synergy, offering a promising approach to overcome therapeutic resistance and reduce recurrence in TNBC.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • STAT3 (Signal Transducer And Activator Of Transcription 3)
|
PD-L1 expression
|
doxorubicin hydrochloride
4d
Chronic antibiotic use exacerbates cortico-hippocampal damage induced by aflatoxin B1 and diethylnitrosamine via oxidative stress and apoptotic pathways. (PubMed, Toxicon)
Wistar rats (n = 45; male) were assigned to Control, DEN (200 mg/kg, i.p.), or AFB1 (2 mg/kg, i.p.) groups, each further divided into saline, Ampicillin (50 mg/kg; p.o), or Ciprofloxacin (12.5 mg/kg; p.o) treatments over 21 days-14 days of antibiotics followed by 7 days of AFB1 or DEN co-treatment. Antibiotic misuse may intensify the neurotoxic effects of AFB1 and DEN by increasing oxido-inflammatory responses and neuronal damage, leading to memory impairment and heightened anxiety-like behaviours. Addressing antibiotic misuse and promoting gut microbiota could improve brain health.
Journal
|
EGFR (Epidermal growth factor receptor) • KDR (Kinase insert domain receptor) • PDGFRB (Platelet Derived Growth Factor Receptor Beta) • STAT3 (Signal Transducer And Activator Of Transcription 3) • MMP2 (Matrix metallopeptidase 2) • HSP90AB1 (Heat Shock Protein 90 Alpha Family Class B Member 1)
4d
Liquiritin Enhances Chemosensitivity to Doxorubicin in Breast Cancer by Promoting Ubiquitination-Mediated Degradation of MCL1. (PubMed, Mol Carcinog)
Additionally, LIQ enhanced the chemosensitivity of DOX in BC xenograft mice. LIQ enhanced DOX chemosensitivity in BC cells and xenograft models by promoting ubiquitination-mediated degradation of MCL1.
Journal
|
MCL1 (Myeloid cell leukemia 1)
|
doxorubicin hydrochloride